FIGURE 6.

Individual group analyses: The therapeutic strategy with moderate-dose autologous MSC decreased dnDSA most significantly. We considered individual treatment response in all separate groups. We observed that late therapeutic strategy with moderate-dose (5 M cells) autologous MSC was associated with the most significant decrease in DSA across 3 isotypes (group T8). IgG1, IgG2a, and IgG2c DSA were most strongly affected by MSC immunomodulation in this group (A, B, C). No significant downregulation was seen for IgM DSA (D). Although most strategies downregulated IgG2a DSA (B), only T5 (10 M allogeneic MSC-preventive infusion schedule), T7 (5 M autologous MSC−preventive infusion schedule), and T8 (5 M autologous MSC−therapeutic infusion schedule) groups showed downregulation of IgG1 (A), and T8 was associated with a decline in IgG2c isotype (C).